Anamitro Banerjee is a Branch Chief in the Office of New Drug Products (ONDP), FDA. His branch supports all the 5 oncology clinical divisions in the OND and the Oncology Center of Excellence. The branch reviews all the INDs and NDAs for small molecules. The branch participates in various OCE initiatives such as the Real Time Oncology Review (RTOR) and Project Orbis. He joined the FDA as a CMC reviewer in 2008. He was a Quality Assessment Lead in the ONDP supporting Division of Transplant and Ophthalmology Products in FDA before his current position. He obtained his PhD in Organic Chemistry from the University of Maryland, College Park and was a postdoctoral fellow at Cornell University.